18-260 - ARST1431 - Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaStatus: open
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Treatment for Pediatric Oncology- Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at email@example.com.
This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
Providers Associated With This Trial
- Hamayun Imran, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics